Secarna Addresses Undruggable Targets With Antisense Platform

 
• By Janelle Hart

At the 2024 BIO International Convention, In Vivo spoke with Secarna Pharmaceuticals' CEO Alexander Gebauer about how the biotech's next-gen antisense oligonucleotide technology aims to benefit patients across multiple indications. 

scientists gathered around a computer analyzing research
scientists gathered analyzing research • Source: Shutterstock

More from Deal-Making

More from In Vivo